share_log

6-K: Statement: Zantac (Ranitidine) Litigation - Settlement Agreements Reached

6-K: Statement: Zantac (Ranitidine) Litigation - Settlement Agreements Reached

聲明：Zantac（雷尼替丁）訴訟-和解協議達到
美股SEC公告 ·  2024/10/09 13:32

Moomoo AI 已提取核心訊息

GSK has reached settlement agreements with 10 plaintiff firms to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion. Additionally, the company agreed to pay $70 million to settle a separate Zantac qui tam complaint filed by Valisure. Both settlements are made with no admission of liability.The settlements are expected to be fully implemented by the end of H1 2025. GSK will recognize an incremental charge of £1.8 billion ($2.3 billion) in Q3 2024 results, covering both settlements and the remaining 7% of pending state court cases. The costs will be funded through existing resources.Despite maintaining that scientific consensus shows no consistent evidence linking ranitidine to cancer risk, GSK views these settlements as strategically beneficial for eliminating financial uncertainty and litigation risks. The company confirmed that these settlements will not affect its growth agenda or R&D investment plans.
GSK has reached settlement agreements with 10 plaintiff firms to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion. Additionally, the company agreed to pay $70 million to settle a separate Zantac qui tam complaint filed by Valisure. Both settlements are made with no admission of liability.The settlements are expected to be fully implemented by the end of H1 2025. GSK will recognize an incremental charge of £1.8 billion ($2.3 billion) in Q3 2024 results, covering both settlements and the remaining 7% of pending state court cases. The costs will be funded through existing resources.Despite maintaining that scientific consensus shows no consistent evidence linking ranitidine to cancer risk, GSK views these settlements as strategically beneficial for eliminating financial uncertainty and litigation risks. The company confirmed that these settlements will not affect its growth agenda or R&D investment plans.
GSk已與10家原告事務所達成和解協議，以解決93%（約80,000件）美國州法院Zantac產品責任案件，和解金額高達22億。此外，公司同意支付7000萬來解決Valisure提出的單獨Zantac qui tam投訴。這兩項和解都是在不承認責任的情況下達成的。預計這些和解將在2025年上半年結束前完全實施。GSk將在2024年第三季度的業績中確認18億英鎊（23億美金）的額外費用，涵蓋這兩項和解以及剩餘的7%待決州法院案件。費用將通過現有資源進行資助。儘管堅持認爲科學共識顯示沒有一致證據表明雷尼替丁與癌症風險相關，GSk仍然認爲這些和解在消除財務不確定性和訴訟風險方面具有戰略價值。公司確認這些和解不會影響其增長計劃或研發投資計劃。
GSk已與10家原告事務所達成和解協議，以解決93%（約80,000件）美國州法院Zantac產品責任案件，和解金額高達22億。此外，公司同意支付7000萬來解決Valisure提出的單獨Zantac qui tam投訴。這兩項和解都是在不承認責任的情況下達成的。預計這些和解將在2025年上半年結束前完全實施。GSk將在2024年第三季度的業績中確認18億英鎊（23億美金）的額外費用，涵蓋這兩項和解以及剩餘的7%待決州法院案件。費用將通過現有資源進行資助。儘管堅持認爲科學共識顯示沒有一致證據表明雷尼替丁與癌症風險相關，GSk仍然認爲這些和解在消除財務不確定性和訴訟風險方面具有戰略價值。公司確認這些和解不會影響其增長計劃或研發投資計劃。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Organon & Co
    OGN
    -- 16.060
    Medicus Pharma
    MDCX
    -- 3.950
    葛蘭素史克
    GSK
    -- 38.300
    禮來
    LLY
    -- 901.595
    安進
    AMGN
    -- 316.620
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日